Department of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.
Circ J. 2010 Jun;74(6):1175-82. doi: 10.1253/circj.cj-09-1045. Epub 2010 Apr 27.
The presence of microvascular obstruction (MVO) after primary ST-segment elevation acute myocardial infarction (STEMI) is associated with a poor outcome. The aim of the paper was to examine the relationship between distinct monocyte subsets and gadolinium-enhanced cardiovascular magnetic resonance (CMR) characteristics of MVO after STEMI.
Seventy-one patients with primary STEMI successfully treated with stenting were enrolled in the study. Two monocyte subsets (CD14(+)CD16(-) and CD14(+)CD16(+)) were measured on flow cytometry on admission and 2, 3, 4, 5, 8 days after the onset of STEMI. CMR was performed 7 days after revascularization to determine MVO on late gadolinium-enhanced imaging. The peak levels of CD14(+)CD16(-) monocytes, but not those of CD14(+)CD16(+) monocytes, were significantly higher in patients with MVO than in those without MVO. A multivariate logistic regression model showed that the post-perfusion peak levels of CD14(+)CD16(-) monocytes remained an independent factor for the presence of MVO (odds ratio=1.53; 95% confidence interval: 1.01-2.32; P=0.04). The absence of MVO was significantly associated with improvement in left ventricular ejection fraction.
Post-reperfusion enhancement of CD14(+)CD16(-) monocytes was associated with MVO in patients with STEMI. The pathophysiologic and therapeutic implications of this association require further study.
急性 ST 段抬高型心肌梗死(STEMI)后存在微血管阻塞(MVO)与预后不良相关。本文旨在研究单核细胞亚群与 STEMI 后 MVO 的钆增强心血管磁共振(CMR)特征之间的关系。
本研究纳入了 71 例成功接受支架置入治疗的原发性 STEMI 患者。在 STEMI 发病后第 2、3、4、5、8 天,通过流式细胞术检测两种单核细胞亚群(CD14+CD16-和 CD14+CD16+)。血管再通后 7 天行 CMR 以确定晚期钆增强图像上的 MVO。与无 MVO 患者相比,MVO 患者的 CD14+CD16-单核细胞峰值水平显著更高,但 CD14+CD16+单核细胞峰值水平无显著差异。多变量逻辑回归模型显示,灌注后 CD14+CD16-单核细胞峰值水平仍是 MVO 存在的独立因素(比值比=1.53;95%置信区间:1.01-2.32;P=0.04)。无 MVO 与左心室射血分数的改善显著相关。
STEMI 患者再灌注后 CD14+CD16-单核细胞的增强与 MVO 相关。需要进一步研究这种相关性的病理生理和治疗意义。